Schwerin Boyle Capital Management Inc. Sells 28,940 Shares of Pfizer Inc. $PFE

Key Points

• Schwerin Boyle Capital Management Inc. has reduced its stake in Pfizer Inc. by 4.0%, selling 28,940 shares during the first quarter, which now contributes 1.8% of its investment portfolio.
• Pfizer reported earnings of $0.78 per share for the last quarter, exceeding analysts' expectations, and had a revenue increase of 10.3% year-over-year.
• The company has announced a quarterly dividend of $0.43, representing a 6.7% yield, with the ex-dividend date set for July 25th.

Schwerin Boyle Capital Management Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 690,485 shares of the biopharmaceutical company's stock after selling 28,940 shares during the quarter. Pfizer accounts for 1.8% of Schwerin Boyle Capital Management Inc.'s investment portfolio, making the stock its 19th largest holding. Schwerin Boyle Capital Management Inc.'s holdings in Pfizer were worth $17,497,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of PFE. Bessemer Group Inc. raised its position in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK boosted its stake in shares of Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after buying an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in Pfizer during the first quarter worth $8,283,000. Alta Advisers Ltd increased its position in shares of Pfizer by 69.6% during the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after purchasing an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC increased its holdings in Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after buying an additional 10,051 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Finally, Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Up 0.3%

Shares of Pfizer stock opened at $25.8250 on Monday. The company has a 50 day simple moving average of $24.70 and a two-hundred day simple moving average of $24.39. The firm has a market cap of $146.83 billion, a PE ratio of 13.74, a PEG ratio of 0.92 and a beta of 0.52. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.